Logo

Exelixis Report Results of Cabometyx (cabozantinib) in P-II PAPMET Study for Patients with Metastatic Papillary Renal Cell Carcinoma

Share this

Exelixis Report Results of Cabometyx (cabozantinib) in P-II PAPMET Study for Patients with Metastatic Papillary Renal Cell Carcinoma

Shots:

  • The P-II SWOG S1500/PAPMET trial involves assessing cabometyx (60 mg- qd with dose reductions to 40 & 20mg )- crizotinib- and savolitinib vs sunitinib in a ratio (1:1:1:1) for patients with advanced or metastatic PRCC
  • The results demonstrated significant improvement in PFS. The trial met its 1EP’s shows mPFS (9.0 mos. vs 5.6 mos.); ORR (23% vs 4%) mOS (20.0 mos. vs 16.4 mos.)
  • The findings were presented at the 2021 ASCO GU and simultaneously published in The Lancet

 ­ Ref: Exelixis | Image: Exelixis

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Related News/Articles

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions